Mate, you’re investing in biotech, and you think the same fundamentals apply as in other industries? Really?
And please don’t twist my words—saying there’s "enough speculative potential for a punt" is not what I said, nor was my post specifically about Incannex. I was talking about biotech.
And frankly, it’s frustrating that every conversation has to be derailed by the same old concerns. We all know the current management issues - no one’s denying that. But does every discussion have to start with the same arguments? It’s getting redundant and feels like an attempt to martyr any other perspective.
This;
https://www.investopedia.com/articles/stocks/11/qualitative-analysis-biotech-companies.aspIt seems to be more aligned with this conversation.